-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hutchison Medicine recently announced that surufatinib was officially approved by the National Medical Products Administration (NMPA) of China for the treatment of advanced pancreatic neuroendocrine tumors (pNETs)
This approval is based on the results of a Chinese phase 3 clinical trial SANET-p (clinicaltrials.
The results showed that compared with the placebo group, the risk of disease progression or death of pNET patients in the sofatinib treatment group was significantly reduced by 51%
SANET-p study primary endpoint results
On December 30, 2020, Sofatinib was approved by the National Food and Drug Administration for the treatment of non-pancreatic neuroendocrine tumors
The results showed that compared with the placebo group, the risk of disease progression or death in the sofatinib treatment group was significantly reduced by 67%
SANET-ep study primary endpoint results
In China, it is estimated that there will be approximately 71,300 newly diagnosed neuroendocrine tumors in 2020
Neuroendocrine tumors (NET) originate from cells that interact with the nervous system or glands that produce hormones
Surufatinib is a new type of oral tyrosine kinase inhibitor with dual activities of anti-angiogenesis and immunomodulation
Reference source: Hutchison Medicine
Original title: Domestic kinase inhibitor! Hutchison Sofantinib (Sutaida®) was approved by the State Food and Drug Administration for a new indication: treatment of advanced pancreatic neuroendocrine tumors!
